Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma.

Rajaraman S, Canjuga D, Ghosh M, Codrea MC, Sieger R, Wedekink F, Tatagiba M, Koch M, Lauer UM, Nahnsen S, Rammensee HG, Mühlebach MD, Stevanovic S, Tabatabai G.

Mol Ther Oncolytics. 2018 Dec 31;12:147-161. doi: 10.1016/j.omto.2018.12.010. eCollection 2019 Mar 29.

2.

A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model.

Nürnberger C, Bodmer BS, Fiedler AH, Gabriel G, Mühlebach MD.

J Virol. 2019 Jan 17;93(3). pii: e01485-18. doi: 10.1128/JVI.01485-18. Print 2019 Feb 1.

PMID:
30429338
3.

Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model.

Bodmer BS, Fiedler AH, Hanauer JRH, Prüfer S, Mühlebach MD.

Virology. 2018 Aug;521:99-107. doi: 10.1016/j.virol.2018.05.028. Epub 2018 Jun 11.

PMID:
29902727
4.

Modular MLV-VLPs co-displaying ovalbumin peptides and GM-CSF effectively induce expansion of CD11b+ APC and antigen-specific T cell responses in vitro.

Gogesch P, Schülke S, Scheurer S, Mühlebach MD, Waibler Z.

Mol Immunol. 2018 Sep;101:19-28. doi: 10.1016/j.molimm.2018.05.017. Epub 2018 May 28.

PMID:
29852456
5.

Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.

Hutzler S, Erbar S, Jabulowsky RA, Hanauer JRH, Schnotz JH, Beissert T, Bodmer BS, Eberle R, Boller K, Klamp T, Sahin U, Mühlebach MD.

Sci Rep. 2017 Dec 4;7(1):16892. doi: 10.1038/s41598-017-16928-8.

6.

Virotherapy Research in Germany: From Engineering to Translation.

Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM.

Hum Gene Ther. 2017 Oct;28(10):800-819. doi: 10.1089/hum.2017.138. Review.

PMID:
28870120
7.

Vaccine platform recombinant measles virus.

Mühlebach MD.

Virus Genes. 2017 Oct;53(5):733-740. doi: 10.1007/s11262-017-1486-3. Epub 2017 Jul 14. Review.

PMID:
28710608
8.

Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective.

Kleinlützum D, Hanauer JDS, Muik A, Hanschmann KM, Kays SK, Ayala-Breton C, Peng KW, Mühlebach MD, Abel T, Buchholz CJ.

Front Oncol. 2017 Jun 26;7:127. doi: 10.3389/fonc.2017.00127. eCollection 2017.

9.

Development of Recombinant Measles Virus-Based Vaccines.

Mühlebach MD, Hutzler S.

Methods Mol Biol. 2017;1581:151-168. doi: 10.1007/978-1-4939-6869-5_9.

PMID:
28374248
10.

APOBEC4 Enhances the Replication of HIV-1.

Marino D, Perković M, Hain A, Jaguva Vasudevan AA, Hofmann H, Hanschmann KM, Mühlebach MD, Schumann GG, König R, Cichutek K, Häussinger D, Münk C.

PLoS One. 2016 Jun 1;11(6):e0155422. doi: 10.1371/journal.pone.0155422. eCollection 2016.

11.

Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors.

Hanauer JR, Gottschlich L, Riehl D, Rusch T, Koch V, Friedrich K, Hutzler S, Prüfer S, Friedel T, Hanschmann KM, Münch RC, Jost C, Plückthun A, Cichutek K, Buchholz CJ, Mühlebach MD.

Mol Ther Oncolytics. 2016 Feb 24;3:16003. doi: 10.1038/mto.2016.3. eCollection 2016.

12.

Suppressing active replication of a live attenuated simian immunodeficiency virus vaccine does not abrogate protection from challenge.

Gabriel B, Fiebig U, Hohn O, Plesker R, Coulibaly C, Cichutek K, Mühlebach MD, Bannert N, Kurth R, Norley S.

Virology. 2016 Feb;489:1-11. doi: 10.1016/j.virol.2015.11.030. Epub 2015 Dec 11.

13.

A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.

Malczyk AH, Kupke A, Prüfer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Eldin HS, Schmidt J, Vergara-Alert J, Süzer Y, Seifried J, Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, Eickmann M, Becker S, Mühlebach MD.

J Virol. 2015 Nov;89(22):11654-67. doi: 10.1128/JVI.01815-15. Epub 2015 Sep 9.

14.

Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response.

Uhlig KM, Schülke S, Scheuplein VA, Malczyk AH, Reusch J, Kugelmann S, Muth A, Koch V, Hutzler S, Bodmer BS, Schambach A, Buchholz CJ, Waibler Z, Scheurer S, Mühlebach MD.

J Virol. 2015 Sep;89(17):9044-60. doi: 10.1128/JVI.00844-15. Epub 2015 Jun 17.

15.

High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus.

Scheuplein VA, Seifried J, Malczyk AH, Miller L, Höcker L, Vergara-Alert J, Dolnik O, Zielecki F, Becker B, Spreitzer I, König R, Becker S, Waibler Z, Mühlebach MD.

J Virol. 2015 Apr;89(7):3859-69. doi: 10.1128/JVI.03607-14. Epub 2015 Jan 21.

16.

A single amino acid substitution in the measles virus F₂ protein reciprocally modulates membrane fusion activity in pathogenic and oncolytic strains.

Heidmeier S, Hanauer JR, Friedrich K, Prüfer S, Schneider IC, Buchholz CJ, Cichutek K, Mühlebach MD.

Virus Res. 2014 Feb 13;180:43-8. doi: 10.1016/j.virusres.2013.12.016. Epub 2013 Dec 22.

PMID:
24368277
17.

Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaques.

Völker I, Bach P, Coulibaly C, Plesker R, Abel T, Seifried J, Heidmeier S, Mühlebach MD, Lauer UM, Buchholz CJ.

Hum Gene Ther Clin Dev. 2013 Mar;24(1):11-22. doi: 10.1089/humc.2012.242. Epub 2013 Apr 3.

PMID:
23692379
18.

DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.

Friedrich K, Hanauer JR, Prüfer S, Münch RC, Völker I, Filippis C, Jost C, Hanschmann KM, Cattaneo R, Peng KW, Plückthun A, Buchholz CJ, Cichutek K, Mühlebach MD.

Mol Ther. 2013 Apr;21(4):849-59. doi: 10.1038/mt.2013.16. Epub 2013 Feb 5.

19.

Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.

Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I, Ball CR, Johnston IC, Lauer UM, Herold-Mende C, Mühlebach MD, Glimm H, Buchholz CJ.

Cancer Res. 2013 Jan 15;73(2):865-74. doi: 10.1158/0008-5472.CAN-12-2221. Epub 2013 Jan 4.

20.

Adherens junction protein nectin-4 is the epithelial receptor for measles virus.

Mühlebach MD, Mateo M, Sinn PL, Prüfer S, Uhlig KM, Leonard VH, Navaratnarajah CK, Frenzke M, Wong XX, Sawatsky B, Ramachandran S, McCray PB Jr, Cichutek K, von Messling V, Lopez M, Cattaneo R.

Nature. 2011 Nov 2;480(7378):530-3. doi: 10.1038/nature10639.

21.

Mutation of a diacidic motif in SIV-PBj Nef impairs T-cell activation and enteropathic disease.

Tschulena U, Sanzenbacher R, Mühlebach MD, Berger A, Münch J, Schindler M, Kirchhoff F, Plesker R, Coulibaly C, Panitz S, Prüfer S, Muckenfuss H, Hamdorf M, Schweizer M, Cichutek K, Flory E.

Retrovirology. 2011 Mar 2;8:14. doi: 10.1186/1742-4690-8-14.

22.

DARPins: an efficient targeting domain for lentiviral vectors.

Münch RC, Mühlebach MD, Schaser T, Kneissl S, Jost C, Plückthun A, Cichutek K, Buchholz CJ.

Mol Ther. 2011 Apr;19(4):686-93. doi: 10.1038/mt.2010.298. Epub 2011 Jan 11.

23.

Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus.

Mühlebach MD, Schaser T, Zimmermann M, Armeanu S, Hanschmann KM, Cattaneo R, Bitzer M, Lauer UM, Cichutek K, Buchholz CJ.

Cancer Res. 2010 Oct 1;70(19):7620-9. doi: 10.1158/0008-5472.CAN-09-4650. Epub 2010 Sep 21.

24.

Functional HIV-2- and SIVsmmPBj- derived lentiviral vectors generated by a novel polymerase chain reaction-based approach.

Kloke BP, Schüle S, Mühlebach MD, Wolfrum N, Cichutek K, Schweizer M.

J Gene Med. 2010 May;12(5):446-52. doi: 10.1002/jgm.1454.

PMID:
20440755
25.

Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer?

Buchholz CJ, Mühlebach MD, Cichutek K.

Trends Biotechnol. 2009 May;27(5):259-65. doi: 10.1016/j.tibtech.2009.02.002. Epub 2009 Mar 25. Review.

PMID:
19327858
26.

Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity.

Funke S, Schneider IC, Glaser S, Mühlebach MD, Moritz T, Cattaneo R, Cichutek K, Buchholz CJ.

Gene Ther. 2009 May;16(5):700-5. doi: 10.1038/gt.2009.11. Epub 2009 Feb 12.

PMID:
19212424
27.

The measles virus fusion protein transmembrane region modulates availability of an active glycoprotein complex and fusion efficiency.

Mühlebach MD, Leonard VH, Cattaneo R.

J Virol. 2008 Nov;82(22):11437-45. doi: 10.1128/JVI.00779-08. Epub 2008 Sep 10.

28.

Targeted cell entry of lentiviral vectors.

Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ.

Mol Ther. 2008 Aug;16(8):1427-36. doi: 10.1038/mt.2008.128. Epub 2008 Jun 24.

29.

Impact of viral accessory proteins of SIVsmmPBj on early steps of infection of quiescent cells.

Wolfrum N, Mühlebach MD, Schüle S, Kaiser JK, Kloke BP, Cichutek K, Schweizer M.

Virology. 2007 Aug 1;364(2):330-41. Epub 2007 Apr 5.

30.

Stable transduction of primary human monocytes by simian lentiviral vector PBj.

Mühlebach MD, Wolfrum N, Schüle S, Tschulena U, Sanzenbacher R, Flory E, Cichutek K, Schweizer M.

Mol Ther. 2005 Dec;12(6):1206-16. Epub 2005 Sep 16.

31.

Genetic engineering of onco/lentivirus hybrids results in formation of infectious but not of replication-competent viruses.

Steidl S, Schüle S, Mühlebach MD, Stitz J, Boller K, Cichutek K, Schweizer M.

J Gen Virol. 2004 Mar;85(Pt 3):665-78.

PMID:
14993652
32.

Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes.

Mühlebach MD, Schmitt I, Steidl S, Stitz J, Schweizer M, Blankenstein T, Cichutek K, Uckert W.

J Mol Med (Berl). 2003 Dec;81(12):801-10. Epub 2003 Oct 24.

PMID:
14576928
33.

A novel lentivirus vector derived from apathogenic simian immunodeficiency virus.

Stitz J, Mühlebach MD, Blömer U, Scherr M, Selbert M, Wehner P, Steidl S, Schmitt I, König R, Schweizer M, Cichutek K.

Virology. 2001 Dec 20;291(2):191-7.

Supplemental Content

Loading ...
Support Center